The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations

The treatment landscape for relapsing forms of multiple sclerosis (RMS) has expanded considerably over the last 10 years with the approval of multiple new disease-modifying therapies (DMTs), and others in late-stage clinical development. All DMTs for RMS are believed to reduce central nervous system...

Descripción completa

Detalles Bibliográficos
Autores principales: Pardo, Gabriel, Jones, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688209/
https://www.ncbi.nlm.nih.gov/pubmed/28879412
http://dx.doi.org/10.1007/s00415-017-8594-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688209/
https://www.ncbi.nlm.nih.gov/pubmed/28879412
http://dx.doi.org/10.1007/s00415-017-8594-9

Ejemplares similares